Certepetide clinical trials
Also written CEND-1 and LSTA1.
How each study uses certepetide is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the certepetide studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2021 (2); 1 more planned to start later
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 2
Lisata Therapeutics, Inc. (3) · Qilu Pharmaceutical Co., Ltd. (2) · Anup Kasi (1) · Australasian Gastro-Intestinal Trials Group (1)
Often tested with
Tested in the same studies.
Irgd (5) · Folfirinox (1) · Cisplatin (1) · Gemcitabine (1) · Folfox protocol (1)
Studies
Open first, then newest update. How each study uses certepetide is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- A Study of CEND-1 With Chemotherapy as First-Line Therapy in Patients With Pancreatic Ductal AdenocarcinomaRecruitingPhase 2Qilu Pharmaceutical Co., Ltd.NCT06261359Written as CEND-1
- A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid TumorsCompletedPhase 2Lisata Therapeutics, Inc.NCT05712356Written as certepetide
- Certepetide Phase 1b/2a Continuous Infusion Trial in mPDACWithdrawnPhase 1/2Lisata Therapeutics, Inc.NCT06592664Written as certepetide
- CEND-1 in Combination with Neoadjuvant FOLFIRINOX with or Without PanitumumabActive, not recruitingPhase 1/2Anup KasiNCT05121038Written as CEND-1
- The ASCEND Study: Gemcitabine and Nab-Paclitaxel With LSTA1 (Certepetide) or Placebo in Patients With Untreated Metastatic Pancreatic Ductal AdenocarcinomaActive, not recruitingPhase 2Australasian Gastro-Intestinal Trials GroupNCT05042128Written as LSTA1
- CEND-1 Injection (QLC12102) in Patients With Advanced Metastatic Pancreatic Ductal AdenocarcinomaCompletedPhase 1/2Qilu Pharmaceutical Co., Ltd.NCT05052567Written as CEND-1
- CEND-1 in Combination With Nabpaclitaxel and Gemcitabine in Metastatic Pancreatic CancerCompletedPhase 1Lisata Therapeutics, Inc.NCT03517176Written as CEND-1
Codes
What other systems call certepetide · ClinicalTrials.gg INT015508
- UNII (FDA) 7PF4546T2PCERTEPETIDEOne source FDA
- NCI Thesaurus C190342CertepetideOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 7PF4546T2P | CERTEPETIDE | One source FDA |
| NCI Thesaurus | C190342 | Certepetide | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.